They weren't getting paid for their lab work, which made them dilute the crap out of this to pay the bills. They are turning the ship around, don't have loans due for 18 months, revs. increasing and due to published acquisition will skyrocket, can't R/S, can't dilute any more, worse case is this just sits here until they can R/S again, which will be months. Best case, as indicated by the company, it is really turning around, they have serious desires to get back into NASDAQ, pursuing $10M from Cigna (remember I said they didn't get paid), and to da moon we go. Pretty good gamble IMO.